$64.26
0.881.39%
Last update: Nov 10, 6:35 PM
TG Therapeutics Inc
TGTXNASDAQ
TG Therapeutics rose 109.2% from $30.30 to a 1-year high of $63.38, ahead of the S&P 500's +10.0%. Its worst day was Aug 3 (−11.3%), and its low came Mar 12 at $26.94.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $0.14 missed the $0.34 estimate on $192.6M revenue (est. $191.8M); FY revenue guidance of $875.0M–$900.0M against the $784.9M consensus.
+4.2% · S&P 500 −0.6%
Story events cover the past 12 months · Times ET
TG Therapeutics closed at its lowest level of the year, 11.1% below where the year started.
−4.0% · S&P 500 −1.5%
EPS of $0.18 missed the $0.27 estimate on $204.9M revenue (est. $200.8M); FY revenue guidance of $925.0M against the $901.0M consensus.
+16.3%, the year's best day · S&P 500 +1.4%
Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 or early
+9.5% · S&P 500 −0.7%
EPS of $0.05 missed the $0.43 estimate on $240.3M revenue (est. $228.9M); FY revenue guidance of $950.0M against the $941.7M consensus.
−11.3%, the year's worst day · S&P 500 +1.4%
TG Therapeutics shares rose 7.3%, while the S&P 500 rose 0.4%.
+7.3% · S&P 500 +0.4%
EPS of $0.35 beat the $0.28 estimate on $259.9M revenue (est. $245.8M); FY revenue guidance of $1.0B against the $961.3M consensus.
+5.9% · S&P 500 +2.4%
Where it ended: a 1-year high close of $63.38 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $0.56, revenue est. $292.5M).
Nothing in the past 12 months.
All TGTX dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for TGTX and SPY from Benzinga historical bars. Not investment advice.
